A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies.
Jingshan HoValerie HeongWei Peng YongRoss SooCheng Ean CheeAndrea WongRaghav SundarYee Liang ThianAnil GopinathanMei Yan PangPriscillia KoeSanthiay Nathan JerajPhyu Pyar SoeMu Yar SoeTiffany TangMatthew C H NgDavid W M TaiTira J Y TanHongmei XuHua ChangYosef LandesmanJatin ShahSharon ShachamSoo Chin LeeDaniel S W TanBoon Cher GohDavid S P TanPublished in: Therapeutic advances in medical oncology (2022)
twice a week given 2 out of 3 weeks. A 1-week drug holiday was needed as our patients could not tolerate the current approved continuous dosing regimens because of persistent grade 3 fatigue, anorexia and hyponatremia.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- small cell lung cancer
- squamous cell carcinoma
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- open label
- emergency department
- physical activity
- depressive symptoms
- preterm birth
- patient reported
- adverse drug
- drug induced
- study protocol